

A phase II study of 5-azacitidine in chronic myelomonocytic leukaemia (CMML)

Submission date 26/11/2008	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 18/12/2008	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 29/03/2022	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

<http://www.cancerhelp.org.uk/trials/a-trial-looking-at-azacitidine-for-chronic-myelomonocytic-leukaemia-cmml201>

Contact information

Type(s)

Scientific

Contact name

Prof David Bowen

Contact details

Bexley Wing 3rd Floor
St James's Institute of Oncology
Beckett Street
Leeds
United Kingdom
LS9 7DF

Additional identifiers

ClinicalTrials.gov (NCT)

NCT01235117

Protocol serial number

HM08/8540

Study information

Scientific Title

5-azacitidine in chronic myelomonocytic leukaemia (CMML): a two stage phase II, non-randomised, single arm, multi-centre, prospective trial

Acronym

CMML201

Study objectives

To assess the safety, tolerability and efficacy of 5-azacitidine in patients with chronic myelomonocytic leukaemia (CMML).

Please note as of 04/11/2009 this record was updated to include extensions to the anticipated start and end dates; the initial trials dates at the time of registration were:

Initial anticipated start date: 15/03/2009

Initial anticipated end date: 15/03/2011

05/03/2013: Please note that as of 17/08/2010, recruitment for this trial closed

Ethics approval required

Old ethics approval format

Ethics approval(s)

Added 04/11/2009:

Northern and Yorkshire Research Ethics Committee on 28/04/2009 (ref: 09/H0903/13)

Amendment 1 on 02/09/2009

Primary study design

Interventional

Study design

Two stage phase II non-randomised single arm multi-centre prospective trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Chronic myelomonocytic leukaemia

Interventions

Patients should be assessed for their suitability for treatment on Day -5 to Day 1 (start of treatment) of each cycle. Patients should be pre-medicated with ondansetron as per local anti-emetic policy. All patients will receive 100 mg/m² of 5-azacitidine on days 1 - 5 by subcutaneous injection. Those patients unable to tolerate the subcutaneous route of drug administration (due to severe local skin reactions) will be withdrawn from the study.

The cycle is repeated every 28 days for at least 6 cycles or until disease progression. After the 6th cycle of treatment all patients will undergo an assessment of response; responders may continue drug administration until loss of response or development of unacceptable toxicity.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

5-azacitidine, ondansentron

Primary outcome(s)

1. To assess the safety and tolerability of 5-azacitidine, monitored throughout the trial
2. To assess the overall response rate, measured at the end of treatment

Key secondary outcome(s)

To assess response of disease to 5-azacitidine, specifically:

1. Incidence of complete remission (CR)/partial remission(PR)
2. Haematological improvement
3. Control of myeloproliferation
4. Incidence of reduction in spleen size by greater than 50%
5. Overall survival
6. Time to acute myeloid leukaemia (AML) transformation of CMML
7. Time to death or AML transformation of CMML
8. Biological correlates

All monitored throughout the trial.

Completion date

01/05/2013

Eligibility**Key inclusion criteria**

1. Patients with newly diagnosed or previously treated CMML-1 or CMML-2 according to World Health Organization (WHO) criteria (2008)
2. Subject is able and willing to sign the informed consent form
3. Age 18 years or over, either sex, at the time of signing the informed consent form
4. WHO performance status of less than or equal to 2 at study entry
5. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days prior to start of study drug
6. WCBP and men with WCBP partners must agree to use adequate contraceptive methods while on study drug and 6 months after the end of the study

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Total final enrolment

30

Key exclusion criteria

1. CMML with eosinophilia and 5q33 abnormality
2. Previous chemotherapy for CMML except hydroxycarbamide
3. Creatinine concentration more than 1.5 x the institutional upper limit of the normal range
4. Pregnant or lactating females
5. Use of any other experimental drug or therapy within 28 days of baseline
6. Known hypersensitivity to azacitidine
7. Other active malignant disease
8. Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B or C
9. Active infection

Date of first enrolment

23/11/2009

Date of final enrolment

01/05/2013

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Bexley Wing 3rd Floor

Leeds

United Kingdom

LS9 7DF

Sponsor information**Organisation**

Leeds Teaching Hospitals NHS Trust (UK)

ROR

<https://ror.org/00v4dac24>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK (CRUK) (UK)

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Funder Name

Celgene Ltd (UK)

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/07/2014		Yes	No
HRA research summary			28/06/2023	No	No
Plain English results		14/08/2014	29/03/2022	No	Yes